Eterna Therapeutics Inc. (NASDAQ:ERNA) Short Interest Update

Eterna Therapeutics Inc. (NASDAQ:ERNAGet Free Report) was the recipient of a large increase in short interest in the month of December. As of December 15th, there was short interest totalling 606,200 shares, an increase of 427.1% from the November 30th total of 115,000 shares. Currently, 1.2% of the company’s shares are short sold. Based on an average daily volume of 712,600 shares, the short-interest ratio is presently 0.9 days.

Eterna Therapeutics Trading Down 10.6 %

Shares of ERNA traded down $0.03 during trading hours on Friday, reaching $0.25. 329,429 shares of the company traded hands, compared to its average volume of 196,117. Eterna Therapeutics has a 12-month low of $0.22 and a 12-month high of $2.63. The firm has a market cap of $1.37 million, a price-to-earnings ratio of -0.03 and a beta of 4.18. The stock’s fifty day moving average price is $0.64 and its 200 day moving average price is $1.29.

About Eterna Therapeutics

(Get Free Report)

Eterna Therapeutics Inc, a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited.

Featured Stories

Receive News & Ratings for Eterna Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eterna Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.